Author picks SLS expecting its cancer treatment trial to drive the stock from $4.89 to $20 in the next couple months.
SLS — LONG The author argues SLS is a biotech with a cancer treatment that is about to finish a successful trial, which will propel the stock from $4.89 to $20 in the next couple months. The catalyst is the nearing trial completion, and the mechanism is that positive trial results will re-rate the stock. No specific risk is stated for SLS in the text.
SLS is a biotech with a cancer treatment thats about to finish a successful trial which will propell its sock from $4.89 to 20 in the next couple months.
This Reddit post, published January 05, 2026, features u/Blue_Smoke369 discussing SLS. 1 trade idea extracted by AI with direction and confidence scoring.
Speakers: u/Blue_Smoke369 · Tickers: SLS